[MARKET ANALYSIS] Stocks gain as diplomacy hopes rise; Hapag-Lloyd lifts outlook, whilst Lindt issues a profit warning

Newsquawk StaffPublished On the live feed at — 2 more headlines followed before this page went public
Newsquawk headlinesUTC

[MARKET ANALYSIS] Gilts outperform ahead of UK PM Burnham, USTs await data, Fed speak and geopolitical updates

Italy sells EUR 6.5bln (vs exp. EUR 5.5-6.5bln) 3.95% 2032 and 4.00% 2036 BTPs

[MARKET ANALYSIS] Stocks gain as diplomacy hopes rise; Hapag-Lloyd lifts outlook, whilst Lindt issues a profit warning

Gas production in Iran's South Pars Phase 11 reaches 1bln cubic feet, IRIB reports

UK sells GBP 4.25bln 4.875% 2036 Gilt: b/c 3.34x (prev. 3.65x), average yield 5.383% (prev. 5.155%), tail 0.5bps (prev. 0.1bps)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • European bourses (STOXX 600 +0.4%) are broadly firmer this morning, with sentiment buoyed by increased hopes of US-Iran diplomacy – although uncertainty remains (see commodities for details). The energy complex has waned off best levels throughout the London morning, which has also helped lift the equities complex.
  • European sectors hold a positive bias. Tech takes the top spot, reversing some of the pressure seen in the prior session. Industrials and Basic Resources complete the top three, with the latter rebounding from the pressure seen on Monday. To the downside, Food Beverage & Tobacco is joined by Energy and Optimised Personal Care.
  • Key Movers: AstraZeneca (+2%, Co. is to invest USD 2bln in Summit Therapeutics), Airbus (-0.7%, Co. faces slower-than-expected deliveries in September, sources say), Hapag-Lloyd (+3.5%, Co. raises outlook for FY26, citing strong market demand and the ongoing positive development of spot freight rates), Lindt (-6%, issues profit warning), Julius Baer (+8%, FINMA concludes investigation).
  • US equity futures are currently trading on either side of the unchanged mark; the NQ (+0.1%) posts mild gains, whilst the ES and RTY are lower by that same magnitude.  Focus today will be on President Trump’s meeting with AI heads, where discussions will be on AI oversight/safety and competition with China. The day ahead is packed with a number of Fed speakers, as well as US JOLTS job openings.
  • It is also worth noting that Trump's pharma tariffs (announced in Apr), will take effect on a number of key nations today. A 15% levy has been put on the EU, South Korea and Switzerland. Some analysts opine that the new measures could see a reduction in medication available to customers, and could even lead to higher prices.  
Context

This is a broad European morning wrap rather than a single catalyst, and the structure is the familiar one: a geopolitical de-escalation bid (US-Iran diplomacy hopes) lifting equities while the energy complex fades off highs, the classic risk-on/oil-down pairing that has recurred whenever Middle East tension premia partially unwind. That transmission channel, crude as the tax on the equity tape, is the thing to watch inverting if diplomacy stalls. The single-stock movers are idiosyncratic and well-flagged: a freight rate-driven guidance raise at a container liner speaks to the spot freight cycle, a profit warning at a premium chocolatier fits the pattern of cocoa-cost squeezes hitting consumer names, and a concluded regulator investigation removing an overhang is a standard relief-rally setup. The tariff note is the slow-burn item: sectoral levies taking effect on allies have historically produced first-day noise in the affected pharma names, with the real read-through arriving via company commentary on supply chains and pricing over subsequent weeks. The calendar ahead, JOLTS and a slate of Fed speakers, is the kind of second-tier data day that has tended to matter only at the margins unless it breaks decisively from trend. As a digest rather than a decision, the signal is in the cross-asset consistency, not any one line.

Related headlines

The whole workspace, free to try.

Try it free